High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004

Roger Paredes, Irene Cheng, Daniel R. Kuritzkes, Ruth E. Tuomala

    Research output: Contribution to journalArticleResearchpeer-review

    7 Citations (Scopus)

    Abstract

    Using a highly sensitive allele-specific polymerase chain reaction assay we detected the M184V mutation for lamivudine resistance in plasma from 9.4% of HIV-1-infected pregnant women enrolled in the Women and Infant Transmission Study between 1998 and 2004. The prevalence of nelfinavir resistance (D30N) was 6.3%. These results suggest a high prevalence of primary lamivudine and nelfinavir resistance among HIV-1-infected pregnant women in the United States, and support routine genotypic resistance testing before initiating mother-to-child-transmission prophylaxis. © 2007 Lippincott Williams & Wilkins, Inc.
    Original languageEnglish
    Pages (from-to)2103-2106
    JournalAIDS
    Volume21
    Issue number15
    DOIs
    Publication statusPublished - 1 Oct 2007

    Fingerprint Dive into the research topics of 'High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004'. Together they form a unique fingerprint.

    Cite this